From CNBC: 2025-04-14 08:38:00

Pfizer halts development of daily weight loss pill after patient experiences liver injury potentially linked to drug. Patient’s liver enzymes recovered after stopping the pill. Pfizer is behind competitors in the GLP-1 market, with analysts estimating industry worth over $150 billion by early 2030s. Other experimental obesity drugs in Pfizer’s pipeline.

Despite discontinuing daily weight loss pill, Pfizer confirms certain form and dose showed potential in late-stage trials. Rate of elevated liver enzymes in patients taking danuglipron in line with approved GLP-1 drugs. Pfizer has other experimental obesity drugs in pipeline, including one targeting GIPR and another once-daily oral GLP-1.

Pfizer’s decision to discontinue weight loss pill adds to setbacks in GLP-1 space. Novo Nordisk’s Rybelsus, the only oral GLP-1 approved by FDA, generated $3.38 billion in sales in 2024. Pfizer focusing on cancer drugs for long-term growth, but emphasizes obesity as key focus. Pfizer’s stock price is recovering after Covid business decline.



Read more at CNBC: Pfizer scraps daily weight loss pill danuglipron after a liver injury